2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T4e3,Biomarkers identify Alzheimer's disease pathology in cognitively unimpaired adults, but the timing and rate of cognitive decline vary widely. This study aimed to identify subgroups of cognitive decline and baseline predictors of heterogeneity in preclinical progression. Data were drawn from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease Study, which enrolled amyloid beta-positive (Aβ+) participants, and the Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) Study, which enrolled amyloid beta-negative (Aβ-) individuals. Latent class mixed-effects models identified cognitive trajectory classes. Associations between class membership and demographic, clinical, and biomarker variables were evaluated. The primary outcome was change in the Preclinical Alzheimer Cognitive Composite. Three trajectory classes were identified: stable, slow decliners, and fast decliners. Higher phosphorylated tau at 217 (p-tau217), smaller hippocampal volume, and elevated tau positron emission tomography were associated with declining classes. About 70% of Aβ+ individuals were stable. Latent class modeling reveals substantial heterogeneity in preclinical trajectories with important implications for prevention trial design.31:T76d,Abstract INTRODUCTION Biomarkers identify Alzheimer's disease pathology in cognitively unimpaired adults, but the timing and rate of cognitive decline vary widely. This study aimed to identify subgroups of cognitive decline and baseline predictors of heterogeneity in preclinical progression. METHODS Data were drawn from the Anti‐Amyloid Treatment in Asymptomatic Alzheimer's Disease Study, which enrolled amyloid beta‐positive (Aβ+) participants, and the Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) Study, which enrolled amyloid beta‐negative (Aβ−) individuals. Latent class mixed‐effects models identified cognitive trajectory classes. Associations between class membership and demographic, clinical, and biomarker variables were evaluated. The primary outcome was change in the Preclinical Alzheimer Cognitive Composite. RESULTS Three trajectory classes were identified: stable, slow decliners, and fast decliners. Higher phosphorylated tau at 217 (p‐tau217), smaller hippocampal volume, and elevated tau positron emission tomography were associated with declining classes. About 70% of Aβ+ individuals were stable. DISCUSSION Latent class modeling reveals substantial heterogeneity in preclinical trajectories with important implications for prevention trial design. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Amyloid Monoclonal Antibody: modality Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Amyloid Monoclonal Antibody (modality). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/modality/Amyloid%20Monoclonal%20Antibody\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Modalities\",\"item\":\"https://www.reachrx.ai/hub/tag/modality\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Amyloid Monoclonal Antibody\",\"item\":\"https://www.reachrx.ai/hub/tag/modality/Amyloid%20Monoclonal%20Antibody\"}]}}"}}]],["$","$L2f",null,{"title":"Amyloid Monoclonal Antibody: Research & Clinical Takeaways","description":"Review evidence by treatment modality: Amyloid Monoclonal Antibody — concise summaries and practical next steps.","papers":[{"doi":"10.1002/alz.71366","pmid":"42015324","title":"Divergent patterns of cognitive decline in preclinical Alzheimer's disease: Implications for secondary prevention trials","journal_title":"Alzheimer's & Dementia","journal_issn":"1552-5260","published_at":"2026-04-22T00:00:00.000Z","url":"https://doi.org/10.1002/alz.71366","source_score":153,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-04-23","doi":"10.1002/alz.71366","days":"30","issn":"1552-5260","rank":"7","field":"Clinical Medicine","score":"153","category":"Clinical Neurology","categories":["Clinical Neurology"],"_categories":["Clinical Neurology"]},"pubmed":{"doi":"10.1002/alz.71366","title":"Divergent patterns of cognitive decline in preclinical Alzheimer's disease: Implications for secondary prevention trials.","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","methods":"","results":"Three trajectory classes were identified: stable, slow decliners, and fast decliners. Higher phosphorylated tau at 217 (p-tau217), smaller hippocampal volume, and elevated tau positron emission tomography were associated with declining classes. About 70% of Aβ+ individuals were stable.","abstract":"$30","keywords":["clinical trial design","cognitive decline","latent class mixed‐effects model","preclinical Alzheimer's disease"],"pubmed_id":"42015324","conclusions":"","publication_date":"2026-04-22T00:00:00"},"crossref":{"DOI":"10.1002/alz.71366","URL":"https://doi.org/10.1002/alz.71366","ISSN":["1552-5260","1552-5279"],"link":[{"URL":"https://alz-journals.onlinelibrary.wiley.com/doi/pdf/10.1002/alz.71366","content-type":"application/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https://alz-journals.onlinelibrary.wiley.com/doi/full-xml/10.1002/alz.71366","content-type":"application/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https://alz-journals.onlinelibrary.wiley.com/doi/pdf/10.1002/alz.71366","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":"4","score":1,"title":["Divergent patterns of cognitive decline in preclinical Alzheimer's disease: Implications for secondary prevention trials"],"author":[{"given":"Runpeng","family":"Li","sequence":"first","affiliation":[{"name":"USC Epstein Family Alzheimer's Therapeutic Research Institute University of Southern California San Diego California USA"}]},{"given":"Oliver","family":"Langford","sequence":"additional","affiliation":[{"name":"USC Epstein Family Alzheimer's Therapeutic Research Institute University of Southern California San Diego California USA"}]},{"given":"Philip S.","family":"Insel","sequence":"additional","affiliation":[{"name":"Department of Psychiatry University of California San Francisco California USA"}]},{"given":"Reisa A.","family":"Sperling","sequence":"additional","affiliation":[{"name":"Center for Alzheimer Research and Treatment Brigham and Women's Hospital Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA"}]},{"given":"Rema","family":"Raman","sequence":"additional","affiliation":[{"name":"USC Epstein Family Alzheimer's Therapeutic Research Institute University of Southern California San Diego California USA"}]},{"given":"Paul S.","family":"Aisen","sequence":"additional","affiliation":[{"name":"USC Epstein Family Alzheimer's Therapeutic Research Institute University of Southern California San Diego California USA"}]},{"given":"Michael C.","family":"Donohue","sequence":"additional","affiliation":[{"name":"USC Epstein Family Alzheimer's Therapeutic Research Institute University of Southern California San Diego California USA"}]}],"funder":[{"id":[{"id":"10.13039/100014392","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100014392","name":"Avid Radiopharmaceuticals","doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100015595","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100015595","name":"GHR Foundation","doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100000009","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100004312","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100000957","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100000049","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000049","name":"National Institute on Aging","award":["U24AG057437"],"award-info":[{"award-number":["U24AG057437"]}],"doi-asserted-by":"publisher"}],"issued":{"date-parts":[[2026,4]]},"member":"311","prefix":"10.1002","source":"Crossref","volume":"22","archive":["Portico"],"created":{"date-time":"2026-04-22T04:11:21Z","timestamp":1776831081000,"date-parts":[[2026,4,22]]},"indexed":{"date-time":"2026-04-30T03:01:35Z","timestamp":1777518095710,"date-parts":[[2026,4,30]]},"license":[{"URL":"http://creativecommons.org/licenses/by/4.0/","start":{"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000,"date-parts":[[2026,4,21]]},"delay-in-days":20,"content-version":"vor"},{"URL":"http://doi.wiley.com/10.1002/tdm_license_1.1","start":{"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000,"date-parts":[[2026,4,1]]},"delay-in-days":0,"content-version":"tdm"}],"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.71366"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2026-01-26"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2026-03-11"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2026-04-21"}],"deposited":{"date-time":"2026-04-28T16:04:14Z","timestamp":1777392254000,"date-parts":[[2026,4,28]]},"issn-type":[{"type":"print","value":"1552-5260"},{"type":"electronic","value":"1552-5279"}],"published":{"date-parts":[[2026,4]]},"publisher":"Wiley","reference":[{"DOI":"10.1001/jamaneurol.2015.3098","key":"e_1_2_9_2_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa2305032","key":"e_1_2_9_3_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1001/jama.2017.6669","key":"e_1_2_9_4_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.nbas.2023.100074","key":"e_1_2_9_5_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.14283/jpad.2024.122","key":"e_1_2_9_6_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.18637/jss.v078.i02","key":"e_1_2_9_7_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_9_8_1","year":"2020","issue":"1","author":"Wu Z","volume":"4","first-page":"459","unstructured":null,"article-title":"Distinct cognitive trajectories in late life and associated predictors and outcomes: a systematic review","journal-title":"J Alzheimers Dis","doi-asserted-by":null},{"DOI":"10.1016/j.jalz.2018.04.004","key":"e_1_2_9_9_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.trci.2019.08.009","key":"e_1_2_9_10_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_9_11_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"A4 Study Team.A4 study data portal. Accessed December 15 2025.https://www.a4studydata.org","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1002/alz.71152","key":"e_1_2_9_12_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_9_13_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"DonohueMC LiR LangfordO A4LEARN vignettes and articles. Accessed December 15 2025.https://github.com/atri‐biostats/A4LEARN/tree/main/vignettes/articles","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1001/jamaneurol.2014.803","key":"e_1_2_9_14_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1109/34.865189","key":"e_1_2_9_15_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/pst.2285","key":"e_1_2_9_16_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1371/journal.pone.0118432","key":"e_1_2_9_17_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.32614/CRAN.package.rpart","key":"e_1_2_9_18_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"TherneauT AtkinsonB rpart: Recursive Partitioning and Regression Trees.2026. doi:10.32614/CRAN.package.rpart","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":null,"key":"e_1_2_9_19_1","year":"1984","issue":null,"author":"Breiman L","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1002/alz.71366"],"article-number":"e71366","content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Alzheimer's & Dementia"],"published-print":{"date-parts":[[2026,4]]},"reference-count":18,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,4,21]]},"references-count":18,"short-container-title":["Alzheimer's & Dementia"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1002/alz.71366","is_oa":true,"title":"Divergent patterns of cognitive decline in preclinical Alzheimer's disease: Implications for secondary prevention trials","updated":"2026-04-26T08:54:43+00:00","published_date":"2026-04-01","best_oa_location":{"url":"https://doi.org/10.1002/alz.71366","pmh_id":null,"url_for_pdf":null,"url_for_landing_page":"https://doi.org/10.1002/alz.71366"}}},"created_at":"2026-05-07T22:49:25.804Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.1002/alz.71366","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1002/alz.71366","tag_type":"brand","value":"Solanezumab","value_numeric":null},{"paper_doi":"10.1002/alz.71366","tag_type":"category","value":"Clinical Neurology","value_numeric":null},{"paper_doi":"10.1002/alz.71366","tag_type":"condition","value":"Preclinical Alzheimer's Disease","value_numeric":null},{"paper_doi":"10.1002/alz.71366","tag_type":"generic","value":"phosphorylated tau 217","value_numeric":null},{"paper_doi":"10.1002/alz.71366","tag_type":"generic","value":"solanezumab","value_numeric":null},{"paper_doi":"10.1002/alz.71366","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1002/alz.71366","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1002/alz.71366","tag_type":"modality","value":"Amyloid Monoclonal Antibody","value_numeric":null},{"paper_doi":"10.1002/alz.71366","tag_type":"modality","value":"Plasma Biomarker","value_numeric":null},{"paper_doi":"10.1002/alz.71366","tag_type":"modality","value":"Positron Emission Tomography","value_numeric":null},{"paper_doi":"10.1002/alz.71366","tag_type":"sample_size","value":"n=1629","value_numeric":1629},{"paper_doi":"10.1002/alz.71366","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1002/alz.71366","tag_type":"study_design","value":"Longitudinal Cohort Study with Latent Class Analysis","value_numeric":null},{"paper_doi":"10.1002/alz.71366","tag_type":"warning","value":"Plasma p-tau217 values are reported in arbitrary assay units (U/mL), not mass concentration (pg/mL); direct comparison to other assay platforms is not possible.","value_numeric":null},{"paper_doi":"10.1002/alz.71366","tag_type":"warning","value":"Solanezumab is listed as the intervention in A4, but this paper does not evaluate treatment efficacy; randomization arm was included only as a covariate. The modality/brand tags reflect the parent trial context.","value_numeric":null},{"paper_doi":"10.1002/alz.71366","tag_type":"warning","value":"The 'practice_changing' impact flag was applied because the power analysis findings directly challenge standard trial design assumptions for preclinical AD, with quantitative implications for enrollment and outcome selection.","value_numeric":null},{"paper_doi":"10.1002/alz.71366","tag_type":"warning","value":"The study design is primarily a secondary analysis of RCT (A4) and observational (LEARN) data using latent class modeling—not a traditional RCT or prospective cohort; level of evidence reflects this hybrid design.","value_numeric":null}],"summaries":{"what_studied":"This study applied latent class mixed-effects models (LCMM) to data from 1,629 cognitively unimpaired older adults (A4 Study: n=1,110 Aβ+; LEARN Study: n=519 Aβ−; median follow-up 6.0 years) to identify subgroups of cognitive trajectory and evaluate baseline biomarkers—including plasma p-tau217, amyloid PET, tau PET, and hippocampal volume—as predictors of class membership, using the Preclinical Alzheimer Cognitive Composite (PACC) as the primary outcome.","key_result":"Three trajectory classes emerged: stable (77%), slow decliners (16%), and fast decliners (7%). About 70% of Aβ+ individuals were cognitively stable. Higher plasma p-tau217 (OR 3.2), greater hippocampal atrophy (OR 3.9), and elevated tau PET (OR 3.6 for fast decliners) were the strongest predictors of declining classes. Power analysis showed trials enrolling Aβ+ stable individuals had only 30–44% power at 2–4 years even assuming 100% treatment benefit, while trials targeting decliners had 93–98% power detecting just 20% of maximum benefit.","limitations":"- Tau PET was available in only 427 of 1,629 participants, limiting generalizability of tau PET findings.\n- Latent class assignments are probabilistic and sensitive to model specification; follow-up may be insufficient to capture long-term change in stable individuals.\n- Highly selected trial-eligible sample may not represent community-dwelling older adults, and unmeasured confounders (comorbidities, lifestyle) were not accounted for.","practice_takeaway":"Most amyloid-positive cognitively unimpaired adults remain stable over a 6-year window, so enriching prevention trials with plasma p-tau217 and tau PET—rather than relying on amyloid positivity alone—may improve power by targeting the minority who actually decline. Trial designs should use simulation-based power calculations that account for this trajectory heterogeneity, not single-effect-size assumptions."}}],"initialOffset":1,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"modality","value":"Amyloid Monoclonal Antibody"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Modalities","href":"/hub/tag/modality"},{"name":"Amyloid Monoclonal Antibody"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"modality","hub_tag_value":"Amyloid Monoclonal Antibody"}}}]]

Papers